SEC Form 4 · accession 0001209191-15-044673
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP, Technical Operations
Period of report
May 15, 2015
Accepted (ET)
May 19, 2015 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 15, 2015 | M | 500 | $6.60 | A | 19,837 | D | |
| Common Stock | May 15, 2015 | S | 500 | $25.00 | D | 19,337 | D | |
| Common Stock | May 18, 2015 | M | 2,500 | $6.60 | A | 21,837 | D | |
| Common StockF2 | May 18, 2015 | S | 500 | $26.695 | D | 21,337 | D | |
| Common StockF3 | May 18, 2015 | S | 500 | $26.679 | D | 20,837 | D | |
| Common StockF3 | May 18, 2015 | S | 500 | $26.684 | D | 20,337 | D | |
| Common StockF4 | May 18, 2015 | S | 1,000 | $26.718 | D | 19,337 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $6.60 | May 15, 2015 | M | 500 | D | — | Dec 11, 2016 | Common Stock | 500 | 7,836 | D |
| Stock Option (Right to Buy)F5 | $6.60 | May 18, 2015 | M | 2,500 | D | — | Dec 11, 2016 | Common Stock | 2,500 | 5,336 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.875, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.02 to $26.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.02 to $26.885, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The Option is fully vested as of September 29, 2010.